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Summary Graft-versus-host disease (GVHD) was induced in Hooded (RtlC) strain rats by means of high
dose total body irradiation (TBI) and subsequent reconstitution with allogeneic bone marrow and spleen cells
from WAG (Rtlu) strain donors. Untreated recipients of allogeneic cells died within 20 days of engraftment,
whereas those treated daily with Cyclosporin A (CyA), given either from the day of receipt of the graft (Day
0) or from Day 4, survived until the end of the experiment (Day 50). If delayed until Day 7, CyA prophylaxis
was totally ineffective. Hooded rats bearing a syngeneic leukaemia were irradiated and reconstituted with
allogeneic bone marrow. During the course of the ensuing graft-versus-host response (GVHR) leukaemia cells
were eradicated from the spleens of the host animals. However, as a consequence of CyA prophylaxis,
whether started on Day 0 or delayed until Day 4, the anti-leukaemia potential of the bone marrow allograft
was completely abrogated. Anti-tumour activity after engraftment was detectable first at Day 7, i.e. the time
at which the GVHR became intractable to the effects of CyA. The results indicate (1) that CyA suppresses
the initial events but not the effector phase of the GVHR, and (2) that the anti-host and anti-tumour action
of the GVHR may be temporally inseparable.
In recent years patients in remission with acute
myeloid leukaemia (AML) have been treated with
high doses of total body irradiation (TBI) in order
to eliminate the remaining malignant cells and
prevent recurrence of the disease (Thomas et al.,
1977). Following TBI a graft of allogeneic bone-
marrow is given to the patient to restore
haematopoiesis and, consequently, the development
of graft-versus-host disease (GVHD) becomes a
major clinical problem. The prophylactic
administration of the immunosuppressive agent
cyclosporin (CyA) to one group of bone-marrow
recipients has led to a dramatic decrease in
mortality from acute GVHD: only 3/63 (5%) of the
patients receiving this drug have died as the result
of acute GVHD, compared with 7/26 (27%) of the
historical controls (who had been
immunosuppressed with methotrexate (MTX)-see
Powles & Morgenstern, 1982). Since the start of
CyA treatment, however, the incidence of recurrent
leukaemia has risen among the long-term survivors
of this series of patients. The European Bone-
Marrow Transplantation groups, also, recently
reported that CyA prophylaxis for marrow-grafted
AML patients was associated with a higher rate of
leukaemic relapse than MTX prophylaxis (Zwaan &
Hermans, 1982). These data suggest that, in
addition to high dose TBI, a subsequent GVHR
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contributes to the elimination of residual leukaemia
cells. Effective prevention of GVHD with CyA
might, therefore, compromise the anti-leukaemia
potential of the bone-marrow graft. A recently
published analysis of their data by the Seattle Bone
Marrow Transplant Team (Weiden et al., 1981) is
consistent with this suggestion. This group, who use
MTX as prophylaxis for GVHD, report an inverse
relationship between the severity of GVHD and the
incidence of leukaemic relapse. The main aims of
the experiments reported here were to determine
whether residual leukaemia could indeed be
destroyed during the course of a GVHR following
allogeneic-marrow transplantation, and, if so, to
examine the consequences of administering CyA to
prevent the development of GVHD.
Materials and methods
Rats
Inbred, microbiologically-defined rats of the Lister
Hooded Cbi (Rtlc) and WAG (Rtlu) strains (from
Olac Laboratories, Oxfordshire) were used in these
experiments; they were maintained in isolators at
our laboratories and used at 12-20 weeks of age.
TBI and bone-marrow reconstitution
Hooded rats were given a lethal exposure (12.5Gy
at a dose rate of 0.13Gymin'-) to a 60Co source
on Day-I of the experiment and reconstituted with
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allogeneic or syngeneic haematopoietic cells 24h
later (Day 0). Each recipient was given a mixture of
5 x 10' bone-marrow and 5 x 10' unfractionated
spleen cells i.v. (henceforth referred to as the "bone-
marrow graft"), as the transfer of WAG bone-
marrow cells alone did not normally give rise to
GVH activity in Hooded rats.
Cyclosporin A
Rats receiving CyA were given the drug orally. CyA
for oral administration was supplied by Sandoz
Ltd., Switzerland, as a solution in oil at
100mgml-. The CyA solution was diluted to
25mgml'1 with olive oil and administered daily at
25mgkg-1 as previously described (Denham et al.,
1980). CyA treatment was started on Days 0, 4 or 7,
after engraftment and continued until the end of
each experiment.
Leukaemia
The tumour used in these experiments was a
Hooded rat leukaemia (HRL) of spontaneous origin
whose natural history and pathogenicity have been
described (Wrathmell, 1976). In the syngeneic host
the HRL is invariably fatal from an inoculum of 10
cells.
Bioassay for the effects of a GVHR on residual
leukaemia
To investigate the effects of a GVHR on leukaemia
cells surviving TBI we employed an experimental
protocol (illustrated in Figure 2) which was
designed to mimic the clinical treatment schedule as
closely as possible. HRL cells (104) were given to
Hooded rats and allowed to grow for 7 days, i.e.
until the leukaemic state was just recognisable
pathologically. Tumour-bearing rats were then
lethally-irradiated and reconstituted with either
allogeneic or syngeneic bone-marrow in the usual
manner. Fourteen days after grafting the spleens
of the reconstituted rats were transferred as single
cell suspensions to normal, untreated, Hooded rats
(one spleen per recipient) and the survival of the
latter followed. Spleens were used for the bioassay of
the HRL because the leukaemia localised and grew
in the spleen at an early stage in the development
of the tumour.
Results
The effects of CyA treatment on the post-
transplantation survival of Hooded rats are shown
in Figure 1. Untreated, allogeneically-reconstituted
rats all died within 20 days of receiving the bone-
marrow graft. Death as the result of GVHD was
accompanied by signs of severe weight loss, hair
loss and scaling skin; the histopathology of
terminally-affected animals confirmed the diagnosis
of GVHD. (It is unlikely, however, that the death
occurring on Day 7 of an animal in Group III
(Figure 1) was the result of GVHD since our
experience indicates that Hooded rats given WAG
Nature of graft given
1 day after 12.5 Gy TBI Death of rats ( indicates survivors)
(I) Syngeneic- -
no CyA _
(11) Syngeneic -
CyA started Day 0
(III) Allogeneic - * * *
no CyA (IV) | *
(IV) Allogeneic -
CyA started Day 0
(V) Allogeneic -
CyA started Day 4
(VI) Allogeneic - * *
CyA started Day 7
5 10 20 30 " 50
Time (days) after reconstitution of bone marrow
Figure 1 Protection against GVHD in Hooded rats with CyA treatment.CYCLOSPORIN A LEUKAEMIA AND GVH DISEASE 793
bone-marrow die between 10 and 20 days after
engraftment.) Cy treatment from Day 0 or Day 4
prevented GVHD. Syngeneically reconstituted rats
(Groups I and II), 10/11 of the rats from Group IV
and 4/5 rats from Group V (Figure 1) survived,
healthy, until the experiment was terminated at Day
50. The two deaths occurring before Day 50 in the
CyA-treated groups were not accompanied by signs
of GVHD (one rat-from Group V-had
overgrown incisors and did not feed properly). CyA
treatment could not prevent GVHD or slow its rate
of progress if delayed until Day 7: the mean
survival times of rats in Groups III and VI (Figure
1) were 16.1 and 14.2 days respectively.
The effects on the tumour of generating a GVHR
in leukaemia-bearing rats and the consequences of
suppressing GVHD with CyA are shown in Figure
2. Tumour cells surviving irradiation in the spleens
of rats receiving an allogeneic bone-marrow graft
were completely eliminated during the course of the
ensuing GVHR, whereas the HRL recurred in
syngeneically reconstituted animals (Groups II and
I in Figure 2). CyA treatment, whether given from
the day of transplantation or delayed for 4 days,
Day
-8 -1 0 +4
1 1 1
t
104 HRL
cells i.v.
abolished the anti-leukaemia effects of the GVHR.
HRL grew at the same rates in allogeneically-
reconstituted, CyA treated rats and in
syngeneically-reconstituted rats (the survival times
of rats in Groups III and I, Figure 2, do not differ
significantly.
As the survival times of rats in Groups III and
IV in Figure 2 did not differ significantly from the
survival times of rats in Group I, it was unlikely
that the transfer of large numbers of WAG cells to
the secondary hosts contributed to the demise of
transferred HRL cells (i.e. that HRL cells were
killed as "innocent bystanders" during an
immunological response of Hooded rats to WAG
cells). Direct evidence against this possibility was
obtained by giving Hooded rats 102 HRL cells each
together with the cell contents of either a complete
WAG rat spleen or a complete Hooded rat spleen.
The mean survival times of rats receiving WAG
spleen cells (6 rats) and those receiving syngeneic
cells (5 rats) were 29.7+6.3 and 30.2+1.6 days
respectively.
In lethally-irradiated recipients the relative
contribution of antigen driven (i.e. in response to
+14
t
12.5 Gy
TBI
A Periods
of CyA treatment
/ graft Spleens removed and inoculated
into Hooded rats
Nature of graft given Death from leukaemia in recipients of spleen cells
to spleen donors from TBI + BM grafted rats ( indicates survivors)
(I) Syngeneic - 0
no CyA
(II) Allogeneic -
no CyA
(Ill) Allogeneic - *- * 0 0 0
CyA started Day 0
(IV) Allogeneic - 0 * - -
CyA started Day 4
,
20 30 40 50 60 " 9 0
Time (days) after transplant of spleen cells
Figure 2 Antileukaemia action of GVHD and its abolition by CyA treatment. The experimental protocol is
illustrated at the top of the figure. Mean survival time of rats in group (I)=35.5+11.5 days, in group
(III) =43.5+7.0 and in group (IV)=44.4+7.5 days. No difference exists between groups (I) and (III) or between
groups (I) and (IV). (In both cases P>0.05, by the Wilcoxon Two Sample Test).
Bl\794 S. DENHAM et al.
host alloantigens) proliferation to the total
proliferative activity of the donor cells in the early
stages of engraftment is hardly known. To
determine whether the transition from CyA-sensitive
to CyA-resistant GVHR could be related to a
significant increase in antigen-induced donor
lymphocyte proliferation between 4 and 7 days after
grafting, we compared the spleen to body weight
ratios of rats reconstituted with allogeneic or
syngeneic cells at 4, 7 and 14 days. Concurrently we
gave similarly reconstituted groups of rats 102 HRL
cells each at the time of grafting (Day 0) to assess
the cumulative effects of the GVHR on the
leukaemia at 4, 7 and 14 days (by the "spleen
transfer" assay) and thereby substantiate the results
of the earlier experiments. The results of these
experiments are shown in the Table.
At Day 4 following reconstitution no effect of the
GVHR on the leukaemia was detectable and,
although the relative spleen weights of the
allogeneically-reconstituted rats were greater than
those of the syngeneically-reconstituted control rats
in Group I (a difference which, using the Wilcoxon
Test, wasjust significant at the 5% level) the data
in Group II were not significantly different at this
time. By the 7th day after receipt of the bone-
marrow graft, however, the spleen/body weight
ratios of the allogeneically reconstituted rats were
significantly greater than those of syngeneically
reconstituted animals in both Groups I and II
(P=0.028 and 0.014 respectively) and the increase
in spleen size was accompanied by the destruction
of leukaemia cells in the allografted rats.
Discussion
Our results confirm previous reports (Borel et al.,
1976; Tutschka et al., 1979) of the efficacy of CyA
as prophylaxis for GVHD and provide a direct
demonstration of the anti-leukaemia potential of the
GVH reaction. The ability of CyA to suppress
GVH reactivity if given within 4 days of grafting
but not if delayed until Day 7 is entirely consistent
with the reported mode of action of this drug in
vitro i.e. that it inhibits the events which initiate an
immune response (Bunjes et al., 1981) but is
relatively ineffective at suppressing the activity of
immunological effectors (Horsburgh et al., 1981).
The time after engraftment at which effector activity
and CyA insensitivity develop in bone-marrow
allografted rats, however, is later than might be
expected from the reported effects of CyA in vitro
-antigen reactive lymphocytes become insensitive
to the drug within 3 days (Horsburgh et al., 1980-
and from the knowledge that, in the parental cell
-+F1 hybrid model for the GVHR, donor cells
enter S within 24h (Ford et al., 1975). The
manifestations of anti-host activity following the
transfer of allogeneic bone-marrow to lethally-
irradiated recipients may, therefore, be related as
much to the rate at which mature effectors are
Table I Development of graft-versus-host and graft-versus-leukaemia activities after allogeneic
reconstitution
% spleen/body wt.
Survival to 90 days
Group I Group II ofrecipients of
HRL: None 102 i.V. Group IIspleens
Cells used for
reconstitution Allogeneic Syngeneic Allogeneic Syngeneic Allogeneic Syngeneic
Days after grafting
4 0.13* 0.09 0.16 0.12 0/5 0/4
±0.01 ±0.01 +0.03 +0.02 (MST=48) (MST==44)
7 0.26 0.14 0.24 0.13 4/4 0/4
+0.05 +0.02 +0.03 +0.02 (MST=22)
14 0.38 0.12 0.33 0.23 7/9 0/4
+0.13 +0.01 +0.03 +0.04 (MST=25)
All rats given 12.5Gy on Day-I and reconstituted on Day 0.
102 HRL cells given on Day 0 with the BM graft.
MST=mean survival time in days.
* =mean +s.d.
Statistical differences between the groups were determined by the Wilcoxon Two-Sample Test.CYCLOSPORIN A LEUKAEMIA AND GVH DISEASE 795
produced as to the time of their maturation and the
significant increases in spleen size between 4 and 7
days after engraftment represent the cumulative
processes of precursor cell division and effector cell
accumulation.
The results show that the GVHR and the graft
versus leukaemia (GVL) potential of the response
develop at the same tempo: the elimination of
leukaemia occurs as the events leading to host
tissue destruction are initiated, i.e. between 4 and 7
days after grafting. Although we could not separate
GVL from GVH reactivity temporally, tumour-free
spleens were removed from animals that were still
alive on Day 7 and had a potential survival of a
further 10 days (cf. Group III, Figure 1). No
attempt was made to "rescue" allogeneically-
reconstituted animals at Day 7 but in future this
might be feasible with the adoption of more
aggressive CyA therapy or the use of less specific
immunosuppressive agents. Although an early
clinical experience indicated that CyA could not
reverse established GVHD (Powles et al., 1978), the
CyA capsules available at that time were probably
not as effective as the drug formulations in current
use. Indeed, in a recent publication, it was reported
that short courses of high dose CyA given orally
and intramuscularly were abie to reverse clinical
episodes of GVHD (Lokiec et al., 1982).
Until the anti-tumour potential of a bone-marrow
allograft can be expressed without life-threatening
consequences for the patient, intentional
exploitation the GVHR for eradication of residual
leukaemia cannot be contemplated. The results of
our experiments indicate that these objectives will
not be achieved using conventional CyA
prophylaxis for GVHD.
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